| Entre 18 ans et 85 ans
- | Pays :
- France
- | Organes :
- Prostate
- | Spécialités :
- Thérapies Ciblées
Extrait
A randomised, double-blind, placebo-controlled trial assessing the efficacy and safety of dutasteride (AVODART™) 0.5 mg in extending the time to PSA doubling in men with prostate cancer and biochemical failure (PSA increase) after radical therapy with curative intent (ARTS – AVODART after radical therapy for prostate cancer study).
Extrait Scientifique
en cours d'intégration;